{
    "clinical_study": {
        "@rank": "25242", 
        "arm_group": [
            {
                "arm_group_label": "SB5", 
                "arm_group_type": "Experimental", 
                "description": "SB5, single dose of 40 mg via subcutaneous injection (study drug)"
            }, 
            {
                "arm_group_label": "EU sourced Humira\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "EU sourced Humira\u00ae, single dose of 40 mg via subcutaneous injection (reference drug)"
            }, 
            {
                "arm_group_label": "US sourced Humira\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "US sourced Humira\u00ae, single dose of 40 mg via subcutaneous injection (reference drug)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the pharmacokinetics, safety, tolerability, and\n      immunogenicity of SB5 and Humira (EU sourced Humira\u00ae and US sourced Humira\u00ae) in healthy\n      subjects."
        }, 
        "brief_title": "Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy subjects\n\n          -  Have a body mass index between 20.0 and 29.9 kg/m\u00b2, inclusive.\n\n        Exclusion Criteria:\n\n          -  History and/or current presence of clinical significant atopic allergy,\n             hypersensitivity or allergic reactions, also including known or suspected clinically\n             relevant drug hypersensitivity to any components of the test and reference\n             investigational product formulation or comparable drugs\n\n          -  Active or latent Tuberculosis or who have a history of Tuberculosis\n\n          -  History of invasive systemic fungal infections or other opportunistic infections\n\n          -  Systemic or local infection, a known risk for developing sepsis and/or known active\n             inflammatory process\n\n          -  Serious infection associated with hospitalisation and/or which required intravenous\n             antibiotics\n\n          -  History of and/or current cardiac disease\n\n          -  Have received live vaccine(s) within 4 weeks prior to Screening or who will require\n             live vaccine(s) between Screening and the final study visit\n\n          -  Intake medication with a half-life > 24 h within 4 weeks or 10 half-lives of the\n             medication prior to investigational product administration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "189", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02144714", 
            "org_study_id": "SB5-G11-NHV", 
            "secondary_id": "2013-005332-15"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "SB5", 
                    "EU sourced Humira\u00ae"
                ], 
                "intervention_name": "SB5", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "SB5", 
                    "US sourced Humira\u00ae"
                ], 
                "intervention_name": "EU sourced Humira\u00ae", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "EU sourced Humira\u00ae", 
                    "US sourced Humira\u00ae"
                ], 
                "intervention_name": "US sourced Humira\u00ae", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany"
                }, 
                "name": "Samsung Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Three Formulations of Adalimumab (SB5, EU Sourced Humira\u00ae and US Sourced Humira\u00ae) in Healthy Subjects", 
        "overall_contact": {
            "last_name": "Samsung Bioepis Information Center", 
            "phone": "+82 32 455 6711"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the concentration-time curve from time zero to infinity (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "71 days"
            }, 
            {
                "measure": "Maximum serum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "71 days"
            }, 
            {
                "measure": "Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "71 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02144714"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Time to Cmax (Tmax)", 
            "safety_issue": "No", 
            "time_frame": "71 days"
        }, 
        "source": "Samsung Bioepis Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Bioepis Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}